Respiratory company FPH has soared over recent years with the COVID outbreak providing a healthy tailwind for the company. We believe this is a strong $18bn business but its priced for ongoing strong growth however we feel much of this tailwind is already priced into the stock and there’s no hurry to be chasing at today’s valuation i.e. COVID is not going away which helps FPH but we can see the consolidation that’s been unfolding in 2021 lasting well into next year
MM is neutral FPH
Add To Hit List
